

TO THE U.S. PATENT AND TRADEMARK OFFICE:

Please stamp the date of receipt of the following documents(s), and return this card to us.

Title of Document(s): Recordation Cover Sheet
Assignment to Portola Pharmaceuticals, Inc. from
Millennium Pharmaceuticals, Inc.

Date Due: N/A


Appln. No.: 60/092,109 (*inter alia*)

Date Mailed: November 25, 2003

File No.: 022104-000000US

Atty/Sec.: WBK:mrv
60089468 v1

FINANCE SECTION
JAN 23 PM 12:26
U.S. PATENT AND TRADEMARK OFFICE



Form PTO-1595

(Rev. 10-02)

OMB No. 0651-0027 (exp. 5/31/2002)

Recordation Form Cover Sheet
PATENTS ONLYU.S. Department of Commerce
U.S. Patent and Trademark Office

Tab settings ⇨⇨⇨ ▼ ▼ ▼ ▼ ▼ ▼ ▼ ▼

To the Honorable Commissioner of Patents and Trademarks. Please record the attached original documents or copy thereof

1. Name of conveying party(ies):

Millennium Pharmaceuticals, Inc.Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No.

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other: _____

Execution Date: November 7, 2003

2. Name and address of receiving party(ies)

Name: Portola Pharmaceuticals, Inc.

Internal Address:

Street Address: 270 E. Grand Avenue, Suite 22City: South San Francisco State: CA ZIP: 94080Additional name(s) and address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No(s):
60/092,109 filed January 15, 1998

B. Patent No(s):

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: William B. Kezer
TOWNSEND AND TOWNSEND AND CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
(415) 576-02006. Total number of applications and patents involved 177. Total fee (37 CFR 3.41): -----\$680.00

- ☐ Enclosed
☒ Authorized to be charged to deposit account

8. Deposit account number: 20-1430

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*William B. Kezer
Name of Person Signing
Atty. Reg. No. 37,369
SignatureNovember 25, 2003
DateTotal number of pages including cover sheet, attachments and documents: 4

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services
Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450



1. Additional name(s) of conveying party(ies):
(Continued from Page 1)
2. Additional name(s) and address(es) of receiving party(ies):
(Continued from Page 1)
3. Additional application number(s) or patent number(s):
(Continued from Page 1)

A. Patent Application No.(s)

09/226,103 filed January 7, 1999
10/619,086 filed July 11, 2003
60/180,208 filed February 4, 2000
60/202,072 filed May 5, 2000
60/230,447 filed September 6, 2000
09/775,812 filed February 5, 2001
10/350,883 filed January 23, 2003
09/920,325 filed July 25, 2002
60/202,075 filed May 5, 2000
60/230,456 filed September 6, 2000
10/275,154 filed May 4, 2001
60/230,446 filed September 6, 2000
60/317,192 filed September 6, 2001
10/237,153 filed September 6, 2002
60/508,564 filed October 3, 2003
60/508,402 filed October 3, 2003

B. Patent No.(s)

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT is being entered into by and between Millennium Pharmaceuticals, Inc., a Delaware corporation ("Assignor"), and Portola Pharmaceuticals, Inc., a Delaware corporation ("Assignee").

WHEREAS Assignor is an owner of the letters patent and patent applications listed on Attachment A (collectively, the "Patents"); and

WHEREAS Assignor has agreed with Assignee for the transfer to it all of Assignor's right, title and interest in and to said Patents, and the inventions therein.

NOW THEREFORE, pursuant to such agreement and in consideration of the sum of One U.S. Dollar-(\$1.00) paid by Assignee to Assignor (the receipt of which Assignor hereby acknowledges), Assignor hereby assigns and transfers to Assignee Assignor's right, title and interest in said inventions and said Patents, and any and all letters patent or patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said Patents, or reissues, reexaminations or extensions of said Patents, and all rights under all applicable intellectual property treaties and conventions, and the full benefits thereof, and all rights, privileges and advantages appertaining thereto, including any and all rights of Assignor to damages, profits or recoveries of any nature for past infringement of said Patents, and the payment of any and all maintenance fees, taxes, and the like, **TO HOLD** the same unto and to the use of Assignee, its successors and assigns during the residue of the respective terms for which the said Patents were or will be granted and during any such terms, and for any and all rights extending from said divisions, continuations, continuations-in-part, reissues, reexaminations and extensions.

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives and assigns that Assignor will, at the cost and expense of the Assignee, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the recordation of this assignment of the Patents to Assignee.

AND Assignor hereby requests the Director of the United States Patent and Trademark Office to issue, to Assignee, any and all Letters Patent of the United States arising from such United States patents and patent applications included in the Patents for the use and behalf of the Assignee, its successors, legal representatives, and assigns.

Executed at Cambridge, Massachusetts this 7th day of November, 2003

Signature: _____

Printed Name: Mark J. Levin


Title: Chairperson, President and Chief Executive Officer

ATTACHMENT A

Assigned Patent Rights

File Ref. No.	Country	Title	Serial No.	Filing Date	Issue Date	Patent No.	Status
MP198-147P1	United States	PLATELET ADP RECEPTOR INHIBITORS	60/092109	1/15/1998			Abandoned
MP198-147P1RN	United States	PLATELET ADP RECEPTOR INHIBITORS	09/226103	1/7/1999			Allowed
MP198-147P1RNCN1	United States	PLATELET ADP RECEPTOR INHIBITORS	10/619086	7/11/2003			Pending
MP198-147P1RNWO	PCT	PLATELET ADP RECEPTOR INHIBITORS	US99/00518	1/8/1999			Expired
MP199-336P1	United States	NOVEL ADP RECEPTOR	60/171622	12/23/1999			Abandoned
MP199-336P1RRCE	United States	METHODS OF IDENTIFYING AGENTS THAT MODULATE P2Y12 RECEPTOR ACTIVITY	09/745842	12/26/2000			Pending
MP199-336P1WO	PCT	P2Y12 RECEPTOR	US00/34998	12/26/2000			Expired
MP100-596P1	United States	PLATELET ADP RECEPTOR INHIBITORS	60/180208	2/4/2000			Abandoned
MP100-596P2	United States	PLATELET ADP RECEPTOR INHIBITORS	60/202072	5/5/2000			Abandoned
MP100-596P3	United States	PLATELET ADP RECEPTOR INHIBITORS	60/230447	9/6/2000			Abandoned
MP100-596P3RN	United States	PLATELET ADP RECEPTOR INHIBITORS	09/775812	2/5/2001			Abandoned
MP100-596P3RNCN1	United States	PLATELET ADP RECEPTOR INHIBITORS	10/350883	1/23/2003			Pending
MP100-596P3RNCN1	United States	PLATELET ADP RECEPTOR INHIBITORS	09/920325	8/2/2001			Pending
MP100-596P3RNCN1WO	PCT	PLATELET ADP RECEPTOR INHIBITORS	US02/23909	7/25/2002			Pending
MP100-596P3RNWO	PCT	PLATELET ADP RECEPTOR INHIBITORS	US01/03585	2/5/2001			Expired
MP100-601P1	United States	BENZOFUSED PLATELET ADP RECEPTOR INHIBITORS	60/202075	5/5/2000			Abandoned
MP100-601P2	United States	BENZOFUSED PLATELET ADP RECEPTOR INHIBITORS	60/230456	9/6/2000			Abandoned
MP100-601P2NUS	United States	HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS	10/275154	5/4/2001			Pending
MP100-601P2NWO	PCT	HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS	US01/14441	5/4/2001			Expired
MP100-609P1	United States	BICYCLIC FUSED HETEROCYCLIC PLATELET ADP RECEPTOR INHIBITORS	60/230446	9/6/2000			Abandoned
MP100-609P2	United States	BICYCLIC FUSED HETEROCYCLIC PLATELET ADP RECEPTOR INHIBITORS	60/317192	9/6/2001			Abandoned
MP100-609P2R	United States	PIPERAZINE AND HOMOPIPERAZINE	10/237153	9/6/2002			Pending

File Ref. No.	Country	Title		Serial No.	Filing Date	Issue Date	Patent No.	Status
			COMPOUNDS					
MP100-609P2WO	PCT		PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS	US02/28618	9/6/2002			Pending
MP103-121P1	United States		2,4-Dioxo-3-Quinazolinylaryl Sulfonylureas	Not yet available	10/3/2003			Pending
MP103-122P1	United States		Substituted Isoquinolinones	Not yet available	10/3/2003			Pending



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021390-002040US
Client Ref. No.: MPI00-596P3RNCP1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 5/9/03

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Hadri

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Scarborough et al.

Application No.: 09/920,325

Filed: August 2, 2001

For: PLATELET ADP RECEPTOR
INHIBITORS

Examiner: Bruck Kifle

Art Unit: 1624

PETITION TO CORRECT INVENTORSHIP
UNDER 37 C.F.R. § 1.48(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants petition under 37 C.F.R. § 1.48(b) to delete inventors Hans-Michael Jantzen and David M. Sedlock from the above-identified patent application. Hans-Michael Jantzen and David M. Sedlock were correctly named as inventors of the present application. However, as a result of amendments of the originally-filed claims, their invention is no longer claimed in the application.

Please deduct the petition fee, pursuant to 37 C.F.R. § 1.17(i), from Deposit Account No. 20-1430 of the undersigned. Please charge any additional fees or credit overpayment to the above Deposit Account.



Scarborough et al.
Application No.: 09/920,325
Page 2

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "William B. Kezer".

William B. Kezer
Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 415-576-0300
WBK:art
WC 9057760 v1